BioSpace News Archive

ResMed (NYSE: RMD, ASX: RMD) today announced that Rob Douglas, president and chief operating officer, will participate in a fireside chat discussion at the 40th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11, 2019, beginning at approximately 10:00 a.m. (Pacific Time) at the Terranea Resort in Rancho Palos Verdes, Calif.

Eagle Pharmaceuticals, Inc. announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the Jefferies 2019 Global Healthcare Conference as follows:

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, will present data from its multiple sclerosis (MS) portfolio at the Consortium of Multiple Sclerosis Centers (CMSC) 2019 Annual Meeting, taking place May 28 – June 1, 2019 in Seattle, WA.

Children’s National Health System (Children’s National) and The HSC Health Care System (HSC) have signed a definitive agreement to create an integrated partnership that will provide seamless care for children and young adults with complex medical needs in Washington, D.C. and across the region.

HeartFlow, Inc. today announced that it has named Dana G. Mead, Jr. as President and Chief Executive Officer (CEO).

Fifty-four million adults in America are looking for a way to manage the pain caused by arthritis.

Ann Arbor SPARK presents its third annual Tech Talk at the Michigan Theater as part of the a2Tech360 series of events. Doors will open at 9 a.m. with the program beginning at 10 a.m

The global throat cancer therapeutics market is expected to post a CAGR of close to 7% during the period 2019-2023, according to the latest market research report by Technavio.

NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the launch of new subsidiary Curadigm, dedicated to redefining the therapeutic balance between bioavailability, toxicity, and efficacy across the pharmaceutical industry.

IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces that it has signed a contract and received the downpayment for the delivery of a Proteus®ONE solution with the European Institute of Oncology (IEO) in Milan, Italy.